Correlation Between VentriPoint Diagnostics and Theralase Technologies

Can any of the company-specific risk be diversified away by investing in both VentriPoint Diagnostics and Theralase Technologies at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining VentriPoint Diagnostics and Theralase Technologies into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between VentriPoint Diagnostics and Theralase Technologies, you can compare the effects of market volatilities on VentriPoint Diagnostics and Theralase Technologies and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in VentriPoint Diagnostics with a short position of Theralase Technologies. Check out your portfolio center. Please also check ongoing floating volatility patterns of VentriPoint Diagnostics and Theralase Technologies.

Diversification Opportunities for VentriPoint Diagnostics and Theralase Technologies

-0.55

Correlation Coefficient

VentriPoint Diagnostics  Theralase Technologies

Excellent diversification

The 3 months correlation between VentriPoint and Theralase is -0.55. Overlapping area represents the amount of risk that can be diversified away by holding VentriPoint Diagnostics and Theralase Technologies in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Theralase Technologies and VentriPoint Diagnostics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on VentriPoint Diagnostics are associated (or correlated) with Theralase Technologies. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Theralase Technologies has no effect on the direction of VentriPoint Diagnostics i.e., VentriPoint Diagnostics and Theralase Technologies go up and down completely randomly.

Pair Corralation between VentriPoint Diagnostics and Theralase Technologies

Assuming the 90 days horizon VentriPoint Diagnostics is expected to under-perform the Theralase Technologies. But the stock apears to be less risky and, when comparing its historical volatility, VentriPoint Diagnostics is 2.3 times less risky than Theralase Technologies. The stock trades about -0.14 of its potential returns per unit of risk. The Theralase Technologies is currently generating about 0.1 of returns per unit of risk over similar time horizon. If you would invest  17.00  in Theralase Technologies on September 13, 2024 and sell it today you would earn a total of  10.00  from holding Theralase Technologies or generate 58.82% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

VentriPoint Diagnostics  vs.  Theralase Technologies

VentriPoint Diagnostics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days VentriPoint Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Theralase Technologies

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Theralase Technologies are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Theralase Technologies showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with VentriPoint Diagnostics and Theralase Technologies

The main advantage of trading using opposite VentriPoint Diagnostics and Theralase Technologies positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if VentriPoint Diagnostics position performs unexpectedly, Theralase Technologies can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Theralase Technologies will offset losses from the drop in Theralase Technologies' long position.

The idea behind VentriPoint Diagnostics and Theralase Technologies pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.